Procedure: Type II variation approval
Country: Global Procedure
Version #: 01/03/2024
Author: Mariya Ivanova
Editor: Daria Kostiuchenko
ID: GP-PhR-VII-SR
Category: Pharmaceuticals
Validity: Until next MA expiration or update
Certified by: Vlad Reznikov
Copyright: Pattern of USA Inc.
SUMMARY
A Type II variation is distinct from a marketing authorization extension (line extension) and may exert a substantial influence on the quality, safety, or efficacy of a medicinal product. In the case of Type II variations involving the incorporation of new therapeutic indications or alterations to previously approved ones falling within the purview of scope C.I.6, the evaluation period is typically extended due to the substantial volume of anticipated data. Consequently, Marketing Authorization Holders (MAHs) are encouraged to provide advance notice of their intent to submit an extension of indication or other alterations to the authorized therapeutic indication, ideally six months before the planned submission.

Must-Have Requirements, Recognized Standards, and Certification:
- Annex A Comparative Table
- Annex IV Elements
- PAM, PSURs if available
- Grouping of Type II variations
- Module 1,2.3,4,5
- Applicable SmPC, or Annexes I, II, IIIA/B
Nice-to-have:
- Confirmation of the original variation
- Pre-submission checklist
Typical Gaps and Deficiencies: Non-eCTD, Insufficient regulatory documentation, confusing dossier presentation
Implementation Period: With a new batch, defined by MAH and NRA or up to a 12-month period
Deliverables: Confirmation of the MA terms adjustment
PHASE |
TASK |
TASK |
START |
DURATION |
Fee |
KPI |
||
NUMBER |
TITLE |
OWNER |
W/M/Q/Y |
in weeks |
3rd Party |
Service |
State |
|
0 |
In-house Pre-Submission Activity |
|||||||
0.1 |
NDA signing or validation |
Executor |
week 1 |
1 |
||||
0.2 |
Contract Closing |
MAH |
week 1 |
1 |
||||
0.3 |
SOW is approved by MAH |
MAH |
week 1 |
1 |
SOW |
|||
0.4 |
POA issuance and shipping |
MAH |
week 2 |
1 |
||||
0.5 |
Invoice is sent to MAH and paid |
MAH |
week 3 |
1 |
POP |
|||
I |
Submission |
|||||||
I.1 |
Information assembling, forwarding to Executor |
MAH |
week 4 |
1 |
||||
I.2 |
Application form and Registration form development |
Executor |
week 5 |
2 |
Application |
|||
I.3 |
Application form and Registration form approval |
MAH |
week 7 |
1 |
||||
I.4 |
NRA payment |
MAH |
week 7 |
1 |
||||
I.5 |
Sub-number Request to NRA |
Executor |
week 8 |
1 |
Sub-number |
|||
I.6 |
Application submission to NRA |
Executor |
week 8 |
1 |
Submission |
|||
II |
Official Evaluation |
|||||||
II.1 |
Official Dossier Evaluation |
NRA |
week 9 |
4 |
||||
II.2 |
Approval (Skip Ph.III) or Query (GoTo Ph.III) |
NRA |
week 13 |
1 |
Approval or Q&A |
|||
III |
Q&A |
|||||||
III.1 |
Analysis and addressing Qs to MAH |
Executor |
week 13 |
1 |
||||
III.2 |
Answering with relevant documents |
MAH |
week 14 |
1 |
||||
III.3 |
Official Response Evaluation |
NRA |
week 15 |
1 |
||||
III.4 |
Approval (GoTo Ph.IV) or Query (Rpt. Ph.III) |
NRA |
week 16 |
1 |
Approval or Q&A |
|||
IV |
Approval |
|||||||
IV.1 |
NRA Conclusion draft verification |
NRA |
week 17 |
1 |
||||
IV.2 |
NRA Conclusion publication |
NRA |
week 18 |
1 |
||||
IV.3 |
State Listing update |
NRA |
week 19 |
1 |
||||
IV.4 |
Reporting to MAH |
Executor |
week 19 |
1 |
Report |
|||
F |
Final Phase In-house Post-Authorization Activity |
|||||||
F.1 |
Service Acceptance Certificate signing |
MAH |
week 20 |
1 |
||||
F.2 |
Final Invoice |
Executor |
week 20 |
1 |
||||
F.3 |
Final Payment |
MAH |
week 21 |
1 |
||||
F.4 |
Contract Termination |
Executor |
week 21 |
1 |
||||
F.5 |
Archiving and limiting access |
Executor |
week 22 |
1 |
Archiving |
Feel free to submit a Request for Proposal (RFP) for a specific country or territory to info@patternofusa.com